Nevro (NYSE:NVRO) today touted results from a trial of its Senza system for treating painful diabetic neuropathy (PDN)-related chronic pain.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,